COVID-19 Vaccine Candidates: 6 Front-Runners - COVID-19 Clinical Trial
Breaking News | COVID-19

COVID-19 Vaccine Candidates: 6 Front-Runners

While the race to develop a COVID-19 vaccine is well underway with over 40 hopeful candidates, only three have entered “Phase I” of clinical trials, the first of three stages of human testing before drug approval.Phase I testing is only a test to see if the vaccine is safe. Researchers won’t know if it’s effective until Phase II is studied. Below is a brief overview of these three candidates, plus three promising ones that are still in earlier stages of development. 

STARTING IN HUMANS (PHASE 1):  

mRNA-1273 – The front-runner in the U.S., which is backed by the NIAID and developed by Moderna Therapeutics, is based upon a specific type of genetic material, mRNA. 

Ad5-nCoV: The front-runner across the globe, Ad5-nCoV, was developed by the Beijing Institute of Biotech and CanSino Biologics, a Chinese biopharmaceutical company. 

ChAdOx1: The University of Oxford is one of the most recent groups to bring its vaccine candidate into human studies — a major milestone. 

STILL IN LABORATORY (PRECLINICAL) 

BNT162: Biopharmaceutical giant Pfizer, along with partner company BioNTech, is working on an mRNA-based vaccine that is similar to Moderna’s model. 

INO-4800: An entirely different technology is being developed by Inovio Pharmaceuticals, a company that uses a proprietary platform for “activation immunotherapy.” 

Sanofi recombinant DNA vaccine (unnamed): Last month, Sanofi Pasteur announced that it was partnering with the U.S. Department of Health and Human Services to create a DNA-based vaccine

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.